Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma
NCT07191249Phase 2Recruiting
- Sponsor
- Tel Aviv Sourasky Medical Center
- Start
- Jan 2026
- Primary completion
- Apr 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of mosunetuzumab in follicular lymphoma (FL), sponsored by Tel Aviv Sourasky Medical Center. Started Jan 2026; status: recruiting.
02
Drugs
mosunetuzumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT07191249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07191249.